-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$12.33162.9% Upside
Adaptive Biotechnologies Corporation Frequently Asked Questions
-
What analysts cover Adaptive Biotechnologies Corporation?
Adaptive Biotechnologies Corporation has been rated by research analysts at BTIG, Piper Sandler, Morgan Stanley in the past 90 days.